טוען...
Idarucizumab for a traumatic head injury patient taking dabigatran
BACKGROUND: Dabigatran is one of the four drugs currently used as a direct oral anticoagulant in Japan. Idarucizumab, which specifically targets dabigatran, was recently approved in Japan. We present a case of intracranial hemorrhage in a traumatic brain injury patient taking dabigatran who was trea...
שמור ב:
הוצא לאור ב: | Int J Emerg Med |
---|---|
Main Authors: | , , , , , , , |
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
Springer Berlin Heidelberg
2018
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6326148/ https://ncbi.nlm.nih.gov/pubmed/31179930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12245-018-0202-y |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|